Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia
2021 · Leukemia · 145 citations
https://doi.org/10.1038/s41375-021-01281-7
M
Marie-Émilie Dourthe
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
68
Papers
651
Citations
14
h-index
17
i10-index
Marie-Émilie Dourthe is an academic researcher from Hôpital Necker-Enfants Malades. The author has contributed to research in topics: Acute Lymphoblastic Leukemia research & CAR-T cell therapy research & Lymphoma Diagnosis and Treatment. The author has an h-index of 14, co-authored 58 publications.
ORCID: 0000-0002-8326-5973Papers by this author
worksA metabolic synthetic lethality of phosphoinositide 3-kinase-driven cancer
2025 · Nature Communications · 9 citations
https://doi.org/10.1038/s41467-025-57225-7
Success of donor‐derived <scp>CAR</scp>‐T cells after failure of autologous <scp>CD19 CAR‐T</scp> cells (tisagenlecleucel) in B‐cell acute lymphoblastic leukaemia
2024 · British Journal of Haematology · 5 citations
https://doi.org/10.1111/bjh.19524
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat